Skip to content

Syndax Pharmaceuticals

US · SNDX #2947 by market cap Listed 2016
8.72 -0.41 -4.49%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/11/5
  • Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    GlobeNewswire · 2026/11/10
  • Rating change
    H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $36
    Market Newswire · 2026/11/3
  • Rating change
    Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37
    Market Newswire · 2026/11/3
  • Company notice
    Syndax Pharmaceuticals | 8-K: Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
    SEC · 2026/11/3
  • Rating change
    Syndax Pharmaceuticals Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
    Dow Jones · 2026/10/13
  • Company notice
    Syndax Pharmaceuticals | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • Rating change
    BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $23
    Market Newswire · 2026/10/13
  • Rating change
    UBS Downgrades Syndax Pharmaceuticals(SNDX.US) to Hold Rating, Maintains Target Price $33
    Market Newswire · 2026/11/3
  • Here's What Analysts Are Forecasting For Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Third-Quarter Results
    Simply Wall St · 2026/11/5
  • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    GlobeNewswire · 2026/11/5
  • Rating change
    HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
    Benzinga · 2026/10/13
  • Rating change
    Syndax Pharmaceuticals (SNDX) Gets a Buy From Barclays
    TipRanks · 2026/10/13
  • Company notice
    Syndax Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Ondrey Aaron
    SEC · 2026/11/13
  • Rating change
    Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57
    Market Newswire · 2026/11/3
  • Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/11/5
  • Company notice
    Syndax Pharmaceuticals | 10-Q: Quarterly report
    SEC · 2026/11/3
  • Rating change
    HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36
    Benzinga · 2026/11/3
  • Company notice
    Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ondrey Aaron
    SEC · 2026/11/13
  • Rating change
    BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/11/3
  • Syndax Pharmaceuticals Suffers Pipeline Blow
    Benzinga · 2026/10/14
  • Rating change
    H.C. Wainwright Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
    TipRanks · 2026/9/22
  • Company notice
    10-Q: Syndax Pharmaceuticals | 10-Q: Q2 2026 Earnings Report
    SEC · 2026/8/5
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Pyxis Oncology (PYXS)
    TipRanks · 2026/10/1
  • Syndax Pharmaceuticals Down Over 17%, On Pace for Largest Percent Decrease Since May 2025 -- Data Talk
    Dow Jones · 2026/10/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Syndax Pharmaceuticals discussion 0 comments

Add a comment